BASEL, Switzerland, PARIS and BETHESDA, Md., July 27, 2012 (GLOBE NEWSWIRE) -- Roche (SIX:RO; ROG) (OTCQX:RHHBY) and AREVA Med, a subsidiary of AREVA, announced today that they have entered into a strategic collaboration to create a novel, advanced alpha radio-immunotherapy platform to target and kill cancer cells. The agreement will focus on malignant disease with a high unmet medical need.
